These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34293233)

  • 1. The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
    Daly EJ; Turkoz I; Salvadore G; Fedgchin M; Ionescu DF; Starr HL; Borentain S; Trivedi MH; Thase ME; Singh JB
    Depress Anxiety; 2021 Nov; 38(11):1120-1130. PubMed ID: 34293233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
    Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
    CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
    Reif A; Bitter I; Buyze J; Cebulla K; Frey R; Fu DJ; Ito T; Kambarov Y; Llorca PM; Oliveira-Maia AJ; Messer T; Mulhern-Haughey S; Rive B; von Holt C; Young AH; Godinov Y;
    N Engl J Med; 2023 Oct; 389(14):1298-1309. PubMed ID: 37792613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
    CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series.
    Pepe M; Bartolucci G; Marcelli I; Simonetti A; Camardese G; Di Nicola M; Sani G
    J Psychiatr Pract; 2023 Jul; 29(4):325-332. PubMed ID: 37449831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
    d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
    J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
    d'Andrea G; Chiappini S; McIntyre RS; Stefanelli G; Carullo R; Andriola I; Zanardi R; Martiadis V; Sensi SL; Sani G; Clerici M; Di Lorenzo G; Vita A; Pettorruso M; Martinotti G
    Am J Geriatr Psychiatry; 2023 Dec; 31(12):1032-1041. PubMed ID: 37479669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
    Caliman-Fontes AT; Leal GC; Correia-Melo FS; Paixão CS; Carvalho MS; Jesus-Nunes AP; Vieira F; Magnavita G; Bandeira ID; Mello RP; Beanes G; Silva SS; Echegaray M; Carvalho LP; Machado P; Sampaio AS; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC
    Trends Psychiatry Psychother; 2023; 45():e20210298. PubMed ID: 34904800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early effects predict trajectories of response to esketamine in treatment-resistant depression.
    Estrade I; Petit AC; Sylvestre V; Danon M; Leroy S; Perrain R; Vinckier F; Mekaoui L; Gaillard R; Advenier-Iakovlev E; Mancusi RL; Poupon D; De Maricourt P; Gorwood P
    J Affect Disord; 2023 Dec; 342():166-176. PubMed ID: 37738705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study).
    Hong JP; Malek AZA; Li CT; Paik JW; Sulaiman AH; Madriaga G; Zhuo J; Siggins S; Fu DJ; Ju PC
    Asia Pac Psychiatry; 2023 Dec; 15(4):e12548. PubMed ID: 37771084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M; Bartova L; Kasper S
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):440-445. PubMed ID: 32570275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
    Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; van Asselt ADI; Touw DJ; Aan Het Rot M; Schoevers RA
    BMC Psychiatry; 2019 Nov; 19(1):375. PubMed ID: 31783823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results.
    Colla M; Offenhammer B; Scheerer H; Kronenberg G; Vetter S; Mutschler J; Mikoteit T; Bankwitz A; Adank A; Schaekel L; Eicher C; Brühl AB; Seifritz E
    J Psychiatr Res; 2024 May; 173():124-130. PubMed ID: 38522166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Esketamine among patients with treatment resistant depression in a 'real world' health-care setting in Israel.
    Dvorak L; Bloemhof-Bris E; Shelef A; Halperin D; Wexler G; Talmon O; Feffer K
    J Psychiatr Res; 2024 Jun; 174():66-72. PubMed ID: 38626563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.
    Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; Spijker J; van der Meij A; van Asselt ADI; Aan Het Rot M; Schoevers RA
    Mol Psychiatry; 2024 Mar; ():. PubMed ID: 38523183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What clinicians need to know about intranasal esketamine for treatment-resistant depression?
    Hope J; Copolov D; Tiller J; Galbally M; Hopwood M; Newton R; Keks NA
    Australas Psychiatry; 2023 Dec; 31(6):841-845. PubMed ID: 37961848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of esketamine administration in a Greek population: a case series.
    Fotiadis P; Tsalkitzi E; Dimellis D; Rantis K; Tsimpiris A; Pagkalos G
    Psychiatriki; 2024 May; ():. PubMed ID: 38814267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use.
    Vendrell-Serres J; Soto-Angona Ó; Rodríguez-Urrutia A; Inzoli B; González AL; Ramos-Quiroga JA
    Clin Psychopharmacol Neurosci; 2024 Feb; 22(1):159-168. PubMed ID: 38247422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.
    Wang YT; Wang XL; Lei L; Guo ZY; Kan FF; Hu D; Gai C; Zhang Y
    Eur J Clin Pharmacol; 2024 Feb; 80(2):287-296. PubMed ID: 38117332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.